- Home
- CMMB vs NYC Comparison
CMMB vs NYC Comparison
Compare CMMB & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- NYC
- Stock Information
- Founded
- CMMB 2004
- NYC 2013
- Country
- CMMB Israel
- NYC United States
- Employees
- CMMB N/A
- NYC N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- NYC Real Estate
- Sector
- CMMB Health Care
- NYC Finance
- Exchange
- CMMB Nasdaq
- NYC Nasdaq
- Market Cap
- CMMB 23.0M
- NYC 27.6M
- IPO Year
- CMMB N/A
- NYC N/A
- Fundamental
- Price
- CMMB $1.21
- NYC $10.55
- Analyst Decision
- CMMB Strong Buy
- NYC
- Analyst Count
- CMMB 2
- NYC 0
- Target Price
- CMMB $9.00
- NYC N/A
- AVG Volume (30 Days)
- CMMB 89.3K
- NYC 3.1K
- Earning Date
- CMMB 05-27-2025
- NYC 05-09-2025
- Dividend Yield
- CMMB N/A
- NYC N/A
- EPS Growth
- CMMB N/A
- NYC N/A
- EPS
- CMMB N/A
- NYC N/A
- Revenue
- CMMB N/A
- NYC $58,397,000.00
- Revenue This Year
- CMMB N/A
- NYC $8.40
- Revenue Next Year
- CMMB N/A
- NYC $1.62
- P/E Ratio
- CMMB N/A
- NYC N/A
- Revenue Growth
- CMMB N/A
- NYC N/A
- 52 Week Low
- CMMB $0.60
- NYC $7.55
- 52 Week High
- CMMB $2.55
- NYC $13.59
- Technical
- Relative Strength Index (RSI)
- CMMB 46.51
- NYC 40.02
- Support Level
- CMMB $1.15
- NYC $10.68
- Resistance Level
- CMMB $1.31
- NYC $11.77
- Average True Range (ATR)
- CMMB 0.09
- NYC 0.64
- MACD
- CMMB -0.00
- NYC -0.09
- Stochastic Oscillator
- CMMB 22.58
- NYC 0.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.